Myasthenia Gravis Disease Market to surpass US $2,538 Mn by 2026

August 05, 2019


Worldwide myasthenia gravis disease market is expected to exceed US $2,538.6 million by the year 2026, according to the latest research available at Market Study Report LLC, report provides extensively data on market share, growth, trends and forecasts for the period 2018-2026.
 

Myasthenia Gravis is connected with the weakness of body muscles which are under voluntary control of an individual and rapid fatigue. The early symptoms of the disease include weakness in arm & leg muscles, difficulties in chewing, swallowing, speech and breathing, double vision, and drooping of eyelids.
 

Reported to be a common occurrence for women aged less than 40 and men aged more than 60, Myasthenia Gravis can impact people of any age. The disease is a result of breakdown of regular communication between nerves and muscles. Though no precise cure has been found, the symptoms of Myasthenia Gravis can be controlled by early and appropriate treatment.
 

The rising desire to prevent deteriorating quality of life as a result of the disease is the major driver of the Myasthenia Gravis disease market. The increasing efforts for the R&D of novel therapies are also contributing to the global market growth.
 

As cited in the report, the major players of the market are concentrating on innovating and launching affordable therapy solutions for the disease. Yet, the growth of Myasthenia Gravis disease market is hampered by the high cost of treatment and negligence about the early symptoms of the disease.
 

The research report studies the Myasthenia Gravis disease market based on various segments such as diagnosis, treatment, region, and end-user. Based on the diagnosis, the market is categorized as Imaging, Electrodiagnostic, Edrophonium Test, and Blood Tests. The imaging market is further fragmented into x-ray, magnetic resonance imaging, and computed tomography among others. In terms of treatment, the classification includes surgery, medication, and HSCT. While on the basis of end-user, the market is segmented as clinics, hospitals, and academic research institutes.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/1695279/
 

In terms of regional contribution, in 2017, North America led the Myasthenia Gravis disease market owing to escalated number of cases of disease in the region. Additionally, Asia Pacific is presumed to generate impressive growth opportunities over the forecast timeframe on account of growing initiatives by private and government organizations for discovering new control treatments for the disease.  The high awareness regarding neuromuscular disorders is cited to be another factor driving the growth of Myasthenia Gravis disease market in Asia Pacific.
 

The key contenders of the Myasthenia Gravis disease market often collaborate with other behemoths operating in the industry to innovate and launch new products to cater to the increasing needs of the customers. The leading players profiled in the report include Shire plc, Alexion Pharmaceutical Inc., CSL Behring, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., Hoffmann-La Roche AG, Valeant Pharmaceutical International Inc., and Grifols S.A.